[Form 4] Definitive Healthcare Corp. Insider Trading Activity
Definitive Healthcare Corp.'s Chief Legal Officer, Jonathan Paris, had 30,591 shares of Class A Common Stock withheld at $0.80 per share to cover tax obligations related to vested Restricted Stock Units (RSUs). Following this transaction, Paris directly holds 872,263 shares of Class A Common Stock. The filing, categorized as "Neutral" in impact and sentiment, details this non-market tax-withholding disposition.
Definitive Healthcare (DH) CEO has shares withheld to cover RSU taxes
Definitive Healthcare Corp. CEO Kevin Coop reported a tax-related share disposition. The company withheld 37,593 shares of Class A common stock at $0.80 per share to cover Coop’s tax withholding obligations upon the settlement of restricted stock units (RSUs). This transaction was not an open-market sale, and following the withholding, Coop directly owns 4,975,229 shares of Class A common stock.
Definitive Healthcare Corp.(NasdaqGS:DH) added to Russell Microcap Value Benchmark Index
Definitive Healthcare Corp. (NasdaqGS:DH) has been added to the Russell Microcap Value Benchmark Index. This news comes alongside other recent developments for the company, including being dropped from the Russell 2000 Value Benchmark and Russell 2000 Dynamic Index,
Why is Definitive Healthcare stock climbing today? By Investing.com
Definitive Healthcare Corp (DH) stock surprisingly climbed 5.1% in after-hours trading despite a dramatic double downgrade from BofA Securities, which cited concerns over commoditization and AI in the healthcare data market. The bounce appears to be a technical relief rally, as the stock hit a 52-week low and BofA's new price target, while pessimistic, was marginally above the after-hours price, potentially clearing an overhang of uncertainty.
Definitive Healthcare Corp. Class A Actuals & Estimates (NASDAQ:DH)
This article provides an overview of Definitive Healthcare Corp. (NASDAQ: DH) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, upcoming earnings dates, and current financial metrics like revenue, net income, and EBITDA.
Definitive Healthcare (NASDAQ: DH) warned by Nasdaq on sub-$1 bid price
Definitive Healthcare (NASDAQ: DH) has received a notice from Nasdaq for failing to meet the minimum $1.00 per share bid price requirement. The company's stock traded below this threshold for 30 consecutive business days, from May 6, 2026, to June 17, 2026. Definitive Healthcare has 180 calendar days, until December 15, 2026, to regain compliance, potentially through actions like a reverse stock split.
Restaurant365 Names Kate Hastings Chief Customer Officer as It Expands Investment in Customer Success
Restaurant365, a leading restaurant management platform, has appointed Kate Hastings as its Chief Customer Officer to enhance customer success and help operators maximize the value of their investment. Hastings, with over 15 years of experience, will oversee all post-sale customer functions, focusing on helping restaurants navigate increasing complexities like rising food costs and profitability management. Her appointment underscores Restaurant365's commitment to enabling customers to translate insights into actionable results and improve their business outcomes.
Definitive Healthcare (Nasdaq:DH) - Stock Analysis
This Simply Wall St analysis provides an overview of Definitive Healthcare (Nasdaq:DH), highlighting that it's trading significantly below its estimated fair value with projected strong earnings growth. Despite its volatile share price history and current unprofitability, analysts have recently raised price targets, citing improved profitability assumptions and product enhancements. The article also details recent product updates, including expanded data coverage and new integrations, alongside past financial performance and analyst sentiment.
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV) and Tectonic Therapeutic (TECX)
This article highlights bullish sentiments from financial analysts regarding three healthcare companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV), and Tectonic Therapeutic (TECX). Barclays and Piper Sandler maintained Buy ratings for Amneal, projecting a 17.2% upside. Elevance Health also received a Buy rating from Barclays and Bernstein, despite a slight projected downside. Tectonic Therapeutic, supported by Wells Fargo and Raymond James with Buy ratings, shows a significant implied upside of 188.8%.
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)
Analysts have provided new ratings for several healthcare companies. Bank of America Securities maintained a Buy rating for Omnicell (OMCL) with a $70.00 price target, while Wells Fargo maintained a Buy rating for Oric Pharmaceuticals (ORIC) with a $25.00 price target. Wells Fargo also maintained a Hold rating for Pfizer (PFE) with a $28.00 price target, noting its proximity to a 52-week low.
Director Hamood receives 189K RSUs at Definitive Healthcare (DH)
Definitive Healthcare director Samuel A. Hamood was granted 189,190 restricted stock units (RSUs) of Class A Common Stock at no cash cost. These RSUs are set to vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting, contingent on his continued service. Following this grant, Hamood directly holds 289,396 Class A shares and indirectly holds an additional 51,582 shares through AMHAM DH LLC.
Definitive Healthcare (DH) grants 189,190 RSUs to director Scott G. Stephenson
Definitive Healthcare (DH) director Scott G. Stephenson was granted 189,190 restricted stock units (RSUs) of Class A Common Stock. These RSUs will vest on the earlier of June 4, 2027, or the company's next annual stockholder meeting, conditional on his continued service. Following this grant, Stephenson directly holds 313,314 shares of Class A Common Stock.
Definitive Healthcare (DH) grants 189,190 RSUs to director Kathleen Winters
Definitive Healthcare Corp. (DH) reported that its director, Kathleen A. Winters, was granted 189,190 restricted stock units (RSUs) of Class A Common Stock. This equity grant, with no purchase price, increases her direct holdings to 308,982 shares. The RSUs are set to vest on the earlier of June 4, 2027, or the company’s next annual stockholders’ meeting, provided she continues her service.
Definitive Healthcare (DH) director awarded 189,190 RSUs, holdings now 315,984 shares
Definitive Healthcare Corp. director Chilukuri Sastry was granted 189,190 restricted stock units (RSUs) on June 4, 2026, increasing his direct holdings to 315,984 shares. These RSUs are a compensation award with no purchase price and will vest on the earlier of June 4, 2027, or the company's next annual meeting, provided Sastry continues his service. This transaction was reported in a Form 4 filing, detailing the award and its vesting conditions.
Definitive Healthcare (DH) investors approve equity plan share increase and pay
Definitive Healthcare Corp. shareholders approved all proposals at their 2026 annual meeting, including the election of three Class II directors, the ratification of Deloitte & Touche LLP as independent auditor, and an increase of 15,000,000 shares to the 2021 Equity Incentive Plan. They also gave non-binding advisory approval to the compensation of named executive officers. These decisions reflect broad investor support for the company's governance and compensation strategies.
Definitive Healthcare (DH) CFO has shares withheld to cover RSU tax bill
Definitive Healthcare Corp.'s CFO, Casey Heller, had 164,377 shares of Class A common stock withheld by the company to cover tax obligations arising from vested restricted stock units (RSUs). This transaction, valued at $0.99 per share, was a tax-withholding disposition rather than a market trade. Following this, Heller still directly holds a significant 1,841,476 shares of Class A common stock, maintaining a substantial equity position in the company.
Definitive Healthcare (DH) CEO sees 66,050 shares withheld for taxes
Definitive Healthcare (DH) CEO Kevin Coop had 66,050 shares of Class A Common Stock withheld at $0.99 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This transaction was a tax disposition, not an open-market sale, and represents a small portion of his total holdings of 5,012,822 Class A shares. The filing indicates a compensation-related event rather than a discretionary stock sale by the CEO.
Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights
Definitive Healthcare (Nasdaq: DH) has announced significant product enhancements to its data and analytics platform, aiming to provide organizations with a clearer view of the healthcare ecosystem. These updates include expanded medical claims coverage, a new integration with HubSpot, direct access to Healthcare Professional (HCP) data within Salesforce, and new AI search capabilities. The enhancements are designed to strengthen the company’s core data foundation and make insights more accessible, helping customers improve their sales, marketing, product development, and strategy with more confident decision-making.
Advent International holds 62,493,676 DH shares (NYSE: DH)
Advent International entities have reported beneficial ownership of 62,493,676 shares of Definitive Healthcare Corp.'s Class A common stock, representing 59.82% of the outstanding shares as of February 23, 2026. This ownership, detailed in a joint Schedule 13G/A filing, indicates shared voting and dispositive power among various Advent funds and related entities. The filing clarifies the control relationships and specific holdings of the Advent group, with the reported percentage based on 104,472,371 Class A shares outstanding.
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN) and Align Tech (ALGN)
This article summarizes analyst ratings for three healthcare companies: Definitive Healthcare Corp (DH), Elanco Animal Health (ELAN), and Align Tech (ALGN). Definitive Healthcare received a Hold rating from Canaccord Genuity, while Elanco Animal Health received a Buy rating from Evercore ISI, and Align Tech also secured a Buy rating from Evercore ISI. The report includes price targets and analyst consensus for each stock, highlighting potential upsides.
Definitive Healthcare (DH) Posts US$9.3 Million Q4 Loss Testing Profit Turnaround Hopes
Definitive Healthcare (DH) reported a Q4 net loss of US$9.3 million and a full-year net loss of US$138.9 million on US$241.5 million in revenue, according to its latest FY 2025 earnings report. While Q4 saw a narrowed loss per share compared to earlier in the fiscal year, the company continues to face significant losses and slow revenue growth. This performance places current optimism about future profitability and a low P/S ratio against historical widening losses and risks like tightening data privacy rules and industry consolidation.
Definitive Healthcare Reports Financial Results for First Quarter 2026
Definitive Healthcare announced its financial results for the first quarter of 2026, reporting revenue of $55.9 million and an Adjusted Net Income of $8.5 million, exceeding the high end of its guidance. The company highlighted improvements in retention rates and successful new customer acquisitions. Definitive Healthcare also provided its financial outlook for the second quarter and full year 2026, anticipating continued profitability and cash flow generation.
Massive goodwill hit but cash-positive quarter for Definitive Healthcare (DH)
Definitive Healthcare (DH) reported a Q1 2026 GAAP net loss of $192.4 million, significantly impacted by a $197.2 million goodwill impairment charge. Despite this, the company achieved positive non-GAAP profitability with Adjusted Net Income of $8.5 million and Adjusted EBITDA of $15.3 million, and generated $11.6 million in operating cash flow. Definitive Healthcare also provided 2026 full-year guidance expecting revenue between $220.0–$226.0 million and Adjusted EBITDA of $55.0–$59.0 million.
Definitive Healthcare posts $192M Q1 loss on $197M impairment
Definitive Healthcare (NASDAQ: DH) reported a Q1 2026 net loss of $(192.4) million, primarily due to a $197.2 million goodwill impairment charge, despite revenue falling 6% year-over-year to $55.9 million. The company achieved adjusted net income of $8.5 million and adjusted EBITDA of $15.3 million, demonstrating profitability on an adjusted basis and strong cash flow from operations. Definitive Healthcare also provided Q2 and full-year 2026 guidance, emphasizing continued focus on profitability and cash generation.
Definitive Healthcare forecasts $220M-$226M FY2026 revenue while guiding Q2 EBITDA margin at 24%-26%
Definitive Healthcare (DH) has provided its financial outlook, forecasting a revenue range of $220 million to $226 million for fiscal year 2026. Additionally, the company expects its Q2 adjusted EBITDA margin to be between 24% and 26%. This guidance offers insight into the company's anticipated financial performance in the near future.
Definitive Healthcare (DH) chair has 12,166 shares withheld for taxes
Definitive Healthcare's executive chairman, Jason Ronald Krantz, had 12,166 Class A common shares withheld at $0.99 per share to satisfy tax obligations related to the vesting of previously reported Restricted Stock Units (RSUs). This transaction was a tax withholding and not an open-market sale. Following this, Krantz directly holds 1,201,438 Class A shares and indirectly benefits from 450,000 shares held in the DH Holdings trust.
Definitive Healthcare (DH) CFO has shares withheld to cover RSU tax obligations
Definitive Healthcare Corp.'s CFO, Casey Heller, had 1,469 shares of Class A Common Stock withheld at $0.99 per share to satisfy tax obligations related to the vesting of previously reported Restricted Stock Units (RSUs) on May 1, 2026. This transaction was a non-market disposition for tax purposes, not a sale. Following this event, Heller directly holds 2,005,853 shares of Class A Common Stock.
Definitive Healthcare to post Q1 results May 7, webcast at 5 p.m. ET
Definitive Healthcare (Nasdaq: DH) announced it will report its Q1 2026 financial results on Thursday, May 7, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET to discuss the results, with replay availability until June 6, 2026. This announcement sets the stage for investor focus on revenue, profitability, and updates to the 2026 guidance.
Definitive Healthcare (NASDAQ: DH) seeks 15M-share increase to equity plan in 2026 proxy
Definitive Healthcare (NASDAQ: DH) is seeking stockholder approval to increase its 2021 Equity Incentive Plan by 15 million shares, bringing the total to 45,972,789 shares. This proposal, part of its 2026 proxy statement, is intended to support future equity grants for employee, director, and consultant compensation. Other proposals include the election of three Class II directors, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory vote on executive compensation.
Definitive Healthcare (NasdaqGS:DH) Stock Forecast & Analyst Predictions
Definitive Healthcare (DH) is forecast to achieve profitability within the next three years, with annual earnings expected to grow by 113.7% and EPS by 93.2% per year. Despite this, revenue is projected to decline at 2.6% annually, and its future return on equity is estimated at 2.5%. Recent analyst updates have led to revised price targets, reflecting factors such as lower fair value estimates, higher discount rates, and adjusted profit margin expectations.
DH SEC Filings - Definitive Healthcare Corp. 10-K, 10-Q, 8-K Forms
This page provides access to Definitive Healthcare (DH) SEC filings, including 10-K, 10-Q, 8-K, and insider trading reports, enhanced with AI-powered summaries and sentiment analysis. It features details on the company's operations, governance, and financial reporting, catering to investors and traders. The most recent filing discussed is an 8-K from July 1, 2025, and a Form 3 insider filing from June 18, 2025, noting the new Chief Legal Officer holds no DH shares.
Definitive Healthcare Corp. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Data
Definitive Healthcare Corp. (NASDAQ: DH) has filed a Form 8-K with the SEC announcing the termination of a material definitive agreement, specifically the Nominating Agreement, on April 3, 2026. This action could impact board composition and corporate governance, potentially leading to price sensitivity for its stock. Investors are advised to monitor future disclosures for further clarity on the long-term implications.
Definitive Healthcare Ends Spectrum Nomination Rights Agreement
Definitive Healthcare (DH) has officially ended its 2021 nominating agreement with private equity affiliate Spectrum, concluding Spectrum’s special board nomination rights. This follows the resignation of Spectrum designee Jeff Haywood from Definitive Healthcare’s board on March 30, 2026. The move simplifies the company's governance structure and is seen as a step away from private equity influence.
Definitive Healthcare ends nominating agreement with Spectrum following board resignation
Definitive Healthcare Corp. (NASDAQ:DH) has terminated its Nominating Agreement with SE VII DHC AIV, L.P. (Spectrum) following the resignation of Spectrum's designated director, Jeff Haywood, from the company's board. The agreement, which allowed Spectrum to nominate a board member if it held at least 5% of the common stock, was formally ended on April 3. This change follows recent financial results where Definitive Healthcare beat revenue expectations but missed on EPS, and saw a lowered price target from Stephens.
Spectrum board nomination rights end at Definitive Healthcare (DH)
Definitive Healthcare (DH) announced the termination of a Nominating Agreement with SE VII DHC AIV, L.P. (Spectrum) on April 3, 2026. This agreement, originally dated September 17, 2021, had granted Spectrum the right to designate one person for Definitive Healthcare's board slate as long as Spectrum beneficially owned at least 5% of the company's common stock. Jeff Haywood, the Spectrum Designee, resigned from the board on March 30, 2026, fully terminating the nomination rights.
Definitive Healthcare ends nominating agreement with Spectrum following board resignation
Definitive Healthcare (NASDAQ:DH) has terminated its Nominating Agreement with SE VII DHC AIV, L.P., also known as Spectrum, following the resignation of Spectrum's designated board member, Jeff Haywood. This agreement had previously granted Spectrum the right to nominate a director if they held at least 5% of the company's outstanding common stock. The termination, effective April 3, 2026, irrevocably ends future nomination rights.
Definitive Healthcare Corp. Files Form 8-K with SEC on March 30, 2026 – Company Details and Filing Information
Definitive Healthcare Corp. (NASDAQ: DH) has filed an 8-K form with the SEC on March 30, 2026, announcing the resignation of Jeff Haywood from its Board of Directors and the Human Capital Management and Compensation Committee. This change is considered significant for the company's corporate governance and investor confidence, though no immediate financial impact was disclosed. The company, incorporated in Delaware, operates in the Services-Prepackaged Software sector and is not classified as an emerging growth company.
Definitive Healthcare Corp. Announces Resignation of Jeff Haywood from Board and as Member of the Human Capital Management and Compensation Committee, Effective March 30, 2026
Definitive Healthcare Corp. announced the resignation of Jeff Haywood from its Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. Following his resignation, the size of the Board was reduced from 9 to 8 members, and the Compensation Committee was reduced from 3 to 2 members. This change was publicly released on April 3, 2026.
Definitive Healthcare director Jeff Haywood resigns from board and committee By Investing.com
Jeff Haywood has resigned from Definitive Healthcare Corp.'s Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations or policies, and consequently, the Board and Compensation Committee sizes have been reduced. This news follows the company's Q4 fiscal 2025 earnings report, which showed mixed results, including exceeding revenue estimates but missing EPS predictions, leading Stephens to lower its price target.
Definitive Healthcare (DH) chair has 45,154 shares withheld for RSU tax obligations
Jason Ronald Krantz, director and executive chairman of Definitive Healthcare Corp. (DH), had 45,154 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from the vesting of Restricted Stock Units (RSUs). This was a tax-withholding disposition by the issuer, not an open-market sale, with the shares valued at $1.09 each. Following this transaction, Krantz directly holds 1,213,604 shares and beneficially owns an additional 450,000 shares through a trust.
Definitive Healthcare (DH) CEO has RSU shares withheld for taxes
Definitive Healthcare Corp.'s CEO, Kevin Coop, had 37,593 shares of Class A Common Stock withheld on April 1, 2026, to cover tax obligations stemming from RSU vesting. This was a tax-withholding disposition, not an open-market sale, and he now directly holds 5,078,872 shares. The event is considered neutral in terms of market impact and sentiment.
Director Jeff Haywood exits Definitive Healthcare (DH) board, shrinking seats
Definitive Healthcare Corp. announced that director Jeff Haywood resigned from its Board of Directors and the Human Capital Management and Compensation Committee, effective March 30, 2026. This resignation was not due to any disagreements with the company's operations. As a result, the board size decreased from nine to eight members, and the Compensation Committee from three to two members, without immediate replacement.
Definitive Healthcare Corp. Hits New 52-Week Low at $1.37
Definitive Healthcare Corp. has reached a new 52-week low of $1.37, marking a significant 76.41% drop in its stock price over the past year. With a market capitalization of $214 million and a P/E ratio of 6.00, the company exhibits limited profitability and has underperformed the S&P 500. This decline reflects ongoing competitive challenges in the Software Products industry.
Definitive Healthcare (DH) price target decreased by 29.12% to 2.82
The article reports that Definitive Healthcare (DH) has had its price target decreased by 29.12% to $2.82. No further details are provided in the snippet.
Definitive Healthcare Corp. (NASDAQ:DH) Given Average Rating of "Reduce" by Brokerages
Definitive Healthcare Corp. (NASDAQ:DH) has received a consensus "Reduce" rating from ten analysts, with an average 12-month target price of $3.52. The stock opened at $1.19, trading significantly below analyst targets and its 200-day simple moving average. Despite the negative sentiment, institutional ownership is high at 98.67%, with firms like Goldman Sachs and AQR notably increasing their stakes.
Definitive Healthcare Corp. (DH) matches Q4 earnings estimates
The article states that Definitive Healthcare Corp. (DH) matched its Q4 earnings estimates. This indicates that the company performed as expected by analysts during the quarter.
Allina to be acquired by large California health system
Allina Health, a major Upper Midwest nonprofit health system, has agreed to be acquired by California-based Sutter Health, creating a combined $26 billion system with 39 hospitals. The merger, awaiting regulatory approval, reflects a trend of healthcare consolidation that has often led to higher prices. Labor unions representing Allina workers have expressed significant concerns about the acquisition's impact on employees, contracts, pension plans, and the potential diversion of charitable assets out of state.
Definitive Healthcare stock holds at Neutral as revenue declines persist By Investing.com
BTIG has maintained its Neutral rating on Definitive Healthcare Corp (NASDAQ:DH) following its Q4 fiscal 2025 earnings report. Despite revenue exceeding estimates, the company experienced a 1.2% year-over-year decline in revenue and a 12% decline in remaining performance obligations, with both total and Enterprise customers decreasing sequentially. Although the stock has suffered a significant plunge, InvestingPro analysis suggests it is undervalued and analysts project a return to profitability in 2026.
Tax-withholding share transfer by Definitive Healthcare (DH) CEO Coop
Definitive Healthcare Corp. CEO Kevin Coop had 175,524 Class A shares withheld by the company at $1.28 per share to cover tax withholding obligations related to the vesting and settlement of previously reported Restricted Stock Units (RSUs). This transaction, identified by transaction code F, was not an open-market sale but an administrative measure. Following this tax-related disposition, Coop directly holds 5,116,465 shares of Definitive Healthcare common stock, maintaining a significant stake in the company.
Zacks Research Downgrades Definitive Healthcare (NASDAQ:DH) to Strong Sell
Zacks Research has downgraded Definitive Healthcare (NASDAQ:DH) to a "strong sell" rating. This follows several other analysts' reports, resulting in an overall average rating of "Reduce" and a consensus price target of $3.52. The stock opened at $1.18, trading down 3.3%, with a market capitalization of $166.8 million and primarily institutional ownership.
